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Abstract: Rasagiline is a second generation, selective, irreversible monoamine oxidase type B 
(MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s disease 
(PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Mono-
therapy for Parkinson’s Disease Outpatients), and has shown ability to reduce off time in more 
advanced PD patients with motor fluctuations in two large placebo-controlled trials (Parkinson’s 
Rasagiline: Efficacy and Safety in the Treatment of “Off”, and Lasting Effect in Adjunct Therapy 
With Rasagiline Given Once Daily). Preclinical data abound to suggest potential for neuropro-
tection by this compound against a variety of neurotoxic insults in cell cultures and in animals. 
The lack of amphetamine metabolites provides an advantage over the first generation MAO-B 
inhibitor selegiline. One large trial has investigated the potential for disease modification in PD 
patients (Attenuation of Disease progression with Azilect Given Once-daily) and preliminary 
results maintain some possible advantage to earlier initiation of the 1 mg/day dose. The clinical 
significance of the difference detected remains a consideration.
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Introduction
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder characterized 
pathologically by the loss of dopamine-producing neurons in the substantia nigra pars 
compacta and Lewy body deposition in multiple brain areas.1 The depletion of nigros-
tiatal dopamine results in dysfunction of communication between the striatum and the 
cortex, leading to motor deficits that include tremor, rigidity, and bradykinesia, and 
to cognitive and behavioral sequelae in many patients. By the time symptoms occur, 
approximately 80% of striatal dopaminergic neurons, and 50% of nigral neurons are 
lost.1 Multiple pharmacologic strategies are employed to overcome the relative dopa-
mine deficiency. These include supplying levodopa, which serves as a substrate for 
creating more dopamine, administering dopamine agonists, which stimulate dopamine 
receptors, anticholinergic drugs, and drugs which inhibit the metabolism of endog-
enous (and exogenous) dopamine to increase the available supply. The latter category 
includes inhibitors of the two major enzymes responsible for dopamine metabolism, 
catechol-o-methyltransferase, and monoamine oxidase. In the US, the first generation 
monoamine oxidase type B (MAO-B) inhibitor, selegiline, and the second generation 
drug, rasagiline, are available for this purpose. Rasagiline offers the advantages of 
increased tolerability, lack of amphetamine metabolites, and approval for monotherapy 
in early PD. Data in cell cultures and animal studies highlight a neuroprotective effect Therapeutics and Clinical Risk Management 2009:5 414
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of rasagiline and clinical trials offer suggestive evidence of 
a possible disease-modifying effect in humans. This review 
will discuss the role of rasagiline in the treatment of PD and 
its potential role in modifying disease progression.
Therapeutic rationale
As PD symptoms are thought to originate from dysfunction 
of nigrostriatal dopamine circuits and their connections, 
various strategies are employed for enhancing dopami-
nergic function. These include providing an exogenous 
substrate for dopamine production (levodopa), stimulating 
endogenous dopamine receptors with dopamine agonists, 
using anticholinergic medications which work by not fully 
understood mechanisms, and inhibition of dopamine metabo-
lism to increase the amount of available endogenous (and 
exogenous) dopamine at nerve terminals.2
Dopamine is metabolized primarily by two enzymatic 
pathways; by catechol-o-methyl transferase (COMT) into 
3-methoxytyramine (3-MT), and by monoamine oxidase 
(MAO) into dihydroxyphenylacetic acid (DOPAC). DOPAC 
is further metabolized by COMT into HVA, and 3-MT is 
metabolized by MAO into HVA. Monoamine oxidase (MAO) 
is embedded in the outer mitochondrial membrane3 and 
appears to be the primary enzyme responsible for dopamine 
metabolism, as 70%–80% of striatal HVA originates from 
DOPAC, and 20%–30% from 3-MT.4 There are two distinct 
isoenzymes, MAO-A and MAO-B. Type A is primarily 
located in the gut and metabolizes catecholamines as well as 
dietary tyramine. It contributes to the oxidative deamination 
of dopamine, serotonin, and norephinephrine.2 Inhibition of 
this isoform has been associated with the “cheese reaction” 
which derives its name from the potential of aged cheeses 
and other tyramine-rich foods to cause a hypertensive crisis. 
Brain MAO, however, is primarily type B.5 MAO-B is the 
largely predominant isoform, comprising over 80% of MAO 
activity, and contributes to most of the metabolic break-
down of dopamine. It also has a role in deaminating beta-
phenylethylamine, which stimulates release of dopamine 
and inhibits its reuptake.5 Therefore, inhibition of MAO-B 
increases available dopamine.
Older monoamine oxidase inhibitors nonselectively 
inhibited both types A and B, whereas newer selective 
drugs specifically target MAO type B. Efficacy of selective 
MAO-B inhibition in treating early PD was initially estab-
lished for selegiline (deprenyl) in DATATOP (Deprenyl and 
Tocopherol Antioxidative therapy of Parkinsonism).6,7 In 
this multicenter placebo-controlled study, 800 patients with 
early, untreated PD were randomized to receive deprenyl 
10 mg/day, tocopherol (vitamin E) 2,000 IU/day, both, or 
placebo. The primary endpoint was time to progression of 
disability sufficient to require levodopa therapy. Secondary 
endpoints were Unified Parkinson’s Disease Rating Score 
(UPDRS) motor scores, and activities of daily living scores.6 
The study concluded that deprenyl, but not tocopherol, had 
a significant impact on delaying progression of disability. 
The hazard ratio for probability of reaching the primary 
endpoint in selegiline vs placebo patients was 0.5 (95% CI: 
0.41–0.62). Deprenyl patients required levodopa at a median 
of approximately nine months later. Benefit in motor scores 
was detected early, within the first three months, highlight-
ing the symptomatic effect of the drug. The difference was 
sustained at the (14 ± 6-month) follow-up,7 but an extension 
of the study (maintaining the blinding of the initial phase) 
involving 310 of the original 800 patients who had not 
reached the primary endpoint determined that after another 
18 months (12 ± 5), the superiority was not sustained.8 This 
emphasizes that a major challenge in drawing conclusions 
regarding disease modification from deprenyl is the inability 
to separate symptomatic benefit from disease modification. 
The measures for assessing course of disease rely on quan-
tifying symptoms. Therefore, the early therapeutic benefit 
is not clearly differentiated from a delay in progression of 
disability.
Nonetheless, based on the results of DATATOP, the US 
Food and Drug Administration (FDA) approved selegiline 
for adjunctive symptomatic therapy in early PD.9 The Zydis 
formulation was subsequently developed, which dissolves 
in the mouth and is buccally absorbed, avoiding effects of 
first-pass metabolism and increasing bioavailability, while 
decreasing amphetamine metabolites.10,11
The second generation MAO-B inhibitor rasagiline was 
subsequently developed and proved to be clinically effective, 
as discussed below. In 2006, rasagiline was the first MAO-B 
inhibitor to receive FDA approval for monotherapy in early 
PD, and was also approved for adjunctive therapy in moderate 
to advanced PD with motor fluctuations.12
Pharmacokinetics and dosing
Rasagiline is a second generation, irreversible MAO-B 
inhibitor which, unlike selegiline, is not a methamphetamine 
derivative. Rather, rasagiline is a secondary cyclic benzyl-
amine and indane derivative5 with the chemical structure 
(n-propargyl-1[r]-aminoindan). It is rapidly absorbed and 
undergoes metabolism by the cytochrome P450 (CYP) hepatic 
enzymes, primarily CYP1A2.5 Therefore, it should be avoided 
in patients with moderate to severe hepatic insufficiency.13 Therapeutics and Clinical Risk Management 2009:5 415
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Co-administration with potent CYP1A2 inducers (such as 
omeprazole) or inhibitors (such as cimetidine) can decrease or 
increase the area under the concentration-time curve (AUC). 
In contrast, selegiline is metabolized by multiple CYP 
enzymes, leading to much greater potential for drug interac-
tions. Rasagiline is five times as potent as selegiline with 
regard to dose required to inhibit MAO-B by 50%.14 Both 
drugs readily cross the blood–brain barrier.14
The primary metabolite of rasagiline is 1-r-aminoindan, 
whereas selegiline is metabolized primarily to desmethylsel-
egiline, l-methamphetamine, and l-amphetamine. Both 
aminoindan and desmethylselegiline have shown evidence 
of antiapoptotic properties in vitro, but the amphetamine 
metabolites may block the neuroprotective effects of the 
latter.15–17 Less than 1% of rasagiline is excreted unchanged 
in the urine.13
Inhibition of MAO-B by rasagiline is irreversible. Platelet 
MAO-B inhibition correlates well with brain MAO-B, and 
serves as a marker of MAO-B activity. This has revealed that 
35% of MAO-B activity was inhibited within one hour of 
administration of 1 mg rasagiline in healthy volunteers.18,19 
(11) C-I-deprenyl PET was able to detect decrease MAO-B 
activity in the thalamus and basal ganglia immediately after 
a 10-day period of administering rasagiline to healthy volun-
teers. Activity returned to normal over six weeks, consistent 
with the half-life for de novo enzyme synthesis. Duration of 
effect as assessed by platelet MAO-B activity appears to be 
approximately two weeks after discontinuation.12,20
Selectivity for MAO-B over MAO-A is lost in a dose-
dependent manner, as determined in a rat study of escalating 
doses.14 The specific dose at which selectivity is lost in 
humans is not fully known.
Evidence for therapeutic efficacy
Monotherapy: TeMPO
The TEMPO trial ([TVP-1012] in Early Monotherapy for 
Parkinson’s disease Outpatients) was a (multicenter) two-
phased, parallel-group, delayed start, randomized, double-
blinded placebo-controlled trial evaluating the symptomatic 
and potentially disease modifying properties of rasagiline. 
In the first phase, 404 early, untreated PD patients were ran-
domized to rasagiline 1 mg, 2 mg, or placebo for 26 weeks. 
The primary endpoint was change in total UPDRS score 
from baseline, and secondary outcomes included UPDRS 
motor score, activities of daily living (ADL) score, quality 
of life (QOL) measure, among others.21 At 26 weeks, both 
dosages of rasagiline were superior to placebo. The total 
change in UPDRS was -4.2 units for the 1 mg dose (95% CI: 
-5.66 to -2.73; p  0.001), and -3.56 for the 2 mg dose 
relative to placebo (95% CI: -5.04 to -2.08; p  0.001). 
Motor subscales were improved over placebo as well: -2.71 
and -1.68 for the 1 mg and 2 mg doses, respectively. Both 
treatment groups were superior to placebo with regard to 
ADL and QOL scores as well.21,22 This provided evidence of 
therapeutic efficacy in monotherapy in early PD.
In the second phase of the study, all patients received 
the 2 mg dose. This delayed start phase was incorporated 
to determine if there was a therapeutic advantage to early 
treatment. If so, the delayed start group would not “catch up” 
with regard to symptomatic improvement. At 52 weeks, a 
statistically significant advantage was maintained in UPDRS 
scores of the early treatment groups, with mean adjusted 
difference of -1.82 (p = 0.05) for 1 mg early dosing over 
placebo, and -2.29 (p = 0.01) for 2 mg early dosing over the 
early placebo group.23 (PSG 04) (Negative numbers indicate 
improved UPDRS scores.) These results seemed to suggest 
less functional decline in the early treatment groups relative 
to early placebo groups.
Open label extension study of the TEMPO study followed 
306 patients on rasagiline for up to 6.5 years. All patients 
took 2 mg/day until May 2000, when the dose was uniformly 
changed to 1 mg/day. Average decline in UPDRS was 
2–3 points per year, which reflected an improvement over 
historical reports of 8–11 UPDRS points/year in placebo 
groups with similar baseline characteristics. After two years 
of treatment, approximately half of the patients were main-
tained without dopaminergic therapy. The beneficial effect 
of early vs delayed start was maintained for the 6.5-year 
period, offering further support for the persistent symptom-
atic benefit of rasagiline, and the potential role in slowing 
symptom progression.19,24,25
At the same time, critics have questioned whether the 
delayed start design is able to distinguish symptomatic 
improvement from disease progression.
Adjunctive therapy: PReSTO, LARGO
Two large placebo-controlled trials have evaluated the role 
of rasagiline as adjunctive therapy to levodopa in PD.
The PRESTO study (Parkinson’s Rasagiline: Efficacy 
and Safety in the Treatment of “Off”) was a 26-week trial of 
472 patients, with an average disease duration of nine years, 
with motor fluctuations on optimized levodopa treatment. 
Each had at least 2.5 hours of “off” time daily (average six 
hours), and was randomized to rasagiline 0.5 mg, 1 mg, or 
placebo. Levodopa dose was sustained (through the course 
of the study) after titration to the assigned dose. Both groups Therapeutics and Clinical Risk Management 2009:5 416
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had significantly greater improvement (reduction) in off time, 
which was the primary endpoint, over placebo: -1.4 hour 
(-23%) in the 0.5 mg group, and -1.8 hour (-29%) in the 
1 mg group, vs -0.9 hour (-15%) for placebo. Furthermore, 
improvements in secondary endpoints of “on” motor scores 
and “off” ADL scores were seen in both rasagiline groups. 
Dyskinesias were more commonly seen, likely attributable to 
restrictions on levodopa reduction, but tolerability was good 
and there was no significant difference in patients discontinu-
ing the study between treatment and placebo groups.26
The LARGO study (Lasting Effect in Adjunct Therapy 
with Rasagiline Given Once Daily) was an 18-week, 
double-blind, randomized, active comparator study which 
compared rasagiline 1 mg daily, entacapone 200 mg with 
each levodopa dose, and matching placebos for their ability 
to reduce “off” time in 687 levodopa-treated patients with 
motor fluctuations. At the end of 18 weeks, the primary 
endpoint was mean change in daily “off” time from baseline. 
Rasagiline significantly reduced “off” time by (-1.18 hours; 
p = 0.0001) relative to placebo, and entacapone had a similar 
effect (-1.2 hours; p  0.0001). Secondary endpoints reach-
ing significance included “on” time without dyskinesia 
(0.85 hours vs 0.03 hours for placebo; p = 0.0005 for both), 
clinical global impression scores, “off” ADL scores, and 
“on” motor scores.27
Evidence for potential neuroprotection
Rasagiline has shown evidence of neuroprotective properties 
in multiple in vitro and in vivo models with various mecha-
nisms of neurotoxicity. The mechanism cannot be solely 
accounted for by MAO-B inhibition.
Rasagiline has shown protection against various neuronal 
insults in cell cultures. These include protection against 
glutamate-induced toxicity in rat hippocampal neuronal 
cultures17 and against apoptotic cell death from deprivation 
of oxygen and glucose, or from serum and nerve growth 
factor in pheochromocytoma (PC12) cells.15,16 Rasagiline 
also demonstrated antiapoptotic activity against peroxynitrite 
from SIN-1-induced DNA damage in human dopaminergic 
neuroblastoma SH-SY5Y cells.28
In vivo evidence of neuroprotection also exists. Rat 
models of PD using 6-OHDA striatal lesioning revealed 
increased survival of dopaminergic neurons subsequently 
treated with rasagiline relative to controls.29 Rodent models 
have also demonstrated improvements in motor function 
after drug-induced dopaminergic dysfunction, and in 
motor and cognitive function post-hypoxia.30 Furthermore, 
rasagiline-treated mice had faster recovery of motor function 
and spatial memory, and less cerebral edema, after closed 
head injury. Stroke models in the rat demonstrated decreased 
infarct sized after MCA occlusion and improved neurological 
severity scores in multiple models.2,31,32
The mechanism for rasagiline’s neuroprotection may in 
part relate to MAO-B inhibition. In primate models of MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminer-
gic neurotoxicity, pretreatment with rasagiline, via MAO-B 
inhibition, is able to interfere with enzymatic conversion of 
MPTP to a potent neurotoxin, also decreasing free radical 
generation which would disrupt mitochondrial respiration 
and lead to cell death.33,34 This has previously been demon-
strated in a rat model as well.35
At the same time, there is evidence that the s-enantiomer 
(TV1022) of rasagiline is neuroprotective to the same extent, 
despite having 1000 times less potency for MAO-B. These 
include studies in animals exposed to head injury and global 
ischemia, and in cell cultures exposed to neurotoxins.36 
Further, the human neuroblastoma SH-SY5Y cell cultures, 
which do not contain MAO-B, also are protected from 
peroxynitrite and 6-OHDA induced apoptosis by rasagiline 
pretreatment.28,37 The mechanism appears to be stabilization 
of mitochondrial membrane potential and prevention of the 
mitochondrial permeability transition pore from opening. 
Activation of proapoptotic substances such as capsace 3 was 
also inhibited by rasagiline.28,37
The propargylamine moiety of rasagiline has also been 
identified as a direct source of neuroprotection36 by protect-
ing mitochondrial viability and preventing the apoptotic 
cascade. Various cellular insults lead to change in the 
permeability of the mitochondrial membrane potential, 
causing opening of the mitochondrial permeability transition 
pore and decline in the membrane potential. This normally 
causes inhibition of the ubiquitin-proteosome complex and 
release of proapoptotic factors.36 Direct binding of the propar-
gylamine moiety, however, prevents downstream activation 
of proapoptotic factors,37–40 partially via activation of anti-
apoptotic factors including Bcl-2 and protein kinase C, and 
also by downregulation of proapoptotic catalysts including 
FAS and Bax protein families.36
Rasagiline offers an advantage over the first-generation 
MAO-B inhibitor selegiline in its lack of amphetamine 
metabolites, which may interfere with neuroprotection.
In a model of  oxygen/glucose deprivation of  rat PC12 cells, 
rasagiline reduced cell death by 45%–55%, whereas selegi-
line reduced cell death by 30%. Addition of 1-r-aminoindan 
(the major rasagiline metabolite) did not deter from its 
benefit, but addition of l-methamphetamine (major selegiline Therapeutics and Clinical Risk Management 2009:5 417
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metabolite) actually enhanced cell death in cultures. Neither 
metabolite was independently neurotoxic in nondeprived 
cells.16 Another study of apoptotic cell death in PC12 cells 
deprived of serum and nerve growth factors found similar 
results of attenuation of the neuroprotection by selegiline by 
its metabolite, whereas interestingly 1-r-aminoindan actually 
had independent protective effects.15
Furthermore, rasagiline was able to protect rat and human 
fetal me encephalic cells from cell death 15%–20% more 
effectively than selegiline, and also to selectively increase 
dopaminergic cell survival.41,42
Results of the in vitro and animal studies above may or 
may not have direct clinical relevance to humans. Even if 
rasagiline can be protective against the various neurological 
insults studied, the ability to protect to human patients from 
PD progression has not been confirmed. The accumulation 
of preclinical data to suggest potential neuroprotective 
properties has been ultimately challenged clinically in the 
ADAGIO study (Attenuation of Disease progression with 
Azilect GIven Once-daily), a randomized, double-blinded, 
multicenter, placebo-controlled trial with a delayed start 
design to assess rasagiline as a possible disease-modifying 
therapy in PD.43 For this study, 1,176 untreated PD patients 
at 129 international sites, with disease duration less than 
18 months were enrolled. In phase I, subjects were random-
ized equally to one of four groups: 1 mg daily for the 
duration of the study, 2 mg/day for the duration of the 
study (early start groups), placebo for phase I followed 
by 1 mg/day, or placebo for phase I followed by 2 mg/day 
(delayed start groups). Phase I and II were 36 weeks each, 
and if additional anti-parkinsonian medications were 
required, a subject would proceed to phase II. No further 
adjustments were allowed in phase II without exiting the 
study. The rationale of the study was that if a true disease-
modifying, and not solely symptomatic, effect existed, the 
separation between early start and placebo groups would 
be maintained at 72 weeks. If the effect was purely symp-
tomatic, the slopes of the curves would be expected to 
converge.43 The three primary efficacy hypotheses would 
assess 1) rate of UPDRS progression in phase I (slope), 
between weeks 12–36, for treated vs placebo groups, 2) 
change from baseline total UPDRS score at 72 weeks for 
each group, and 3) noninferiority of the slope of early start 
groups (1 or 2 mg rasagiline) vs delayed start groups in 
phase II, weeks 48–72. Secondary outcomes included total 
change in UPDRS during phase I, percentage of subjects 
requiring additional antiparkinsonian medication, and time 
until additional therapy is required.
Although the results of ADAGIO have not yet been 
published, they were presented at both the 12th Congress 
of the European Federation of Neurological Societies, in 
Madrid, Spain in August 2008 and at American Neurological 
Association meeting in December 2008.44 Early treatment 
with 1 mg/day rasagiline reached all three primary endpoints: 
superiority of slope in weeks 12–36 (-0.05; p = 0.013, 95% 
CI: -0.08, -0.01), change from baseline UPDRS to week 72 
(-1.7 units; p = 0.025, 95% CI: -3.15, -0.21), and noninferi-
ority of slope in weeks 48–72 for the early start group (0.0; 
90% CI: -0.04, 0.04). Interestingly, the 2 mg/day dose did 
not meet the endpoint for change in UPDRS from baseline 
to week 72. The clinical significance of the 1.7 unit differ-
ence in the total UPDRS score (ie, combined score of all 
UPDRS subscores) is somewhat controversial. Furthermore, 
the inferior performance of the higher 2 mg dose relative to 
the 1 mg dose is difficult to account for. These results await 
peer review, but the study seems to have demonstrated that 
1 mg was safe, and possibly disease-modifying.
Tolerability
Rasagiline was very well tolerated in clinical trials. Adverse 
events (AEs) were no more frequent than in the placebo 
group in the TEMPO trial.21 The most common AEs 
observed in the first six months (during which placebo was 
available for comparison) were infection (16%) and head-
ache (12%). Serious AEs (malignancy or hospitalizations) 
occurred in four placebo patients, six taking 1 mg/day, and 
10 on 2 mg/day. In the second six months, when everyone 
received 2 mg/day, the most common AEs were infection 
(10.8), headache (5.4%), unintentional injury (4.9%), and 
dizziness (4.6).2,21 Early withdrawal rates were not statisti-
cally different between placebo and treatment groups. In the 
open-label extension phase up to 6.5 years after initiation, 
tolerability remained good even when administered along 
with dopaminergic therapies. Most common AEs reported 
were infection, accidental injury, nausea, and arthralgia. By 
the end of the extension phase, 43 of the original 398 patients 
had withdrawn due to AE.24 In the LARGO study, adverse 
events were similar to placebo, and in PRESTO, rasagiline 
patients had greater gastrointestinal side effects, anorexia 
and weight loss, balance trouble, and dyskinesias. Serious 
adverse effects were rare, and included accidental injury (six), 
arthritis, worsening PD, melanoma, stroke, infection (three 
each). Depression was less common with rasagiline therapy 
than in the placebo group.26 Treatment discontinuation rates 
in PRESTO and LARGO combined were 4.2% for rasagiline 
and 4.9% for placebo.26Therapeutics and Clinical Risk Management 2009:5 418
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Tyramine
Nonselective MAO inhibitors are known to have risk for 
tyramine reactions (“cheese reaction”) or hypertensive crises 
when the drugs inhibit the peripheral metabolism of tyra-
mine, which is found in certain aged cheeses, sausages, and 
wines. Rasagiline, a selective MAO-B inhibitor, when used 
in the therapeutic dosing range, does not seem to carry this 
risk. No tyramine reactions were reported in any of the three 
phase III clinical trials of rasagiline in PD, despite the fact 
that no dietary restrictions were imposed in any of them.19 
Tyramine challenges have been studied in doses that exceed 
those practically achieved by dietary exposure (50–75 mg 
challenges), and no clinically significant hypertension (“pres-
sor response”) could be elicited.45 Still, because the exact 
dose where selectivity for MAO type B is lost is not yet 
characterized, the FDA maintained the requirement for a 
warning in package labeling.
Serotonin
Serious reactions have been reported when nonselective 
MAO inhibitors, or selegiline were used together with a selec-
tive serotonin/norepinephrine reuptake inhibitors (SSRI or 
SNRI). These have included mental status changes, motor and 
autonomic symptoms. In PRESTO, 77 patients took SSRIs 
concomitantly with rasagiline, and no adverse interactions 
were reported.26 The Parkinson Study Group was surveyed 
to determine frequency of serotonin syndrome and found that 
11 cases were seen in 4,568 patients treated with the combina-
tion of eldepryl and an antidepressant, suggesting a frequency 
of 0.24%. Of these, only two patients (0.04%) experienced 
serious side effects, and no deaths were reported.46 It should 
be mentioned that these studies may not have included all 
SSRIs, nor the full range of doses encountered in practice. 
Because the possibility of serotonin syndrome has not been 
adequately ruled out with rasagiline, avoidance of combina-
tion with tricyclic or tetracyclic antidepressants, SSRIs, or 
SNRIs is advised.
Conclusion
Clinical trials support the use of once daily rasagiline for 
symptomatic improvement in patients with early PD. Data 
suggests that delaying the use of rasagiline by six months 
may lead to poorer outcomes. More long-term data is needed 
to clarify the duration of this separation in symptom benefit. 
Rasagiline improves “on” time in patients with advanced PD 
and motor fluctuations on levodopa, similar to the benefit 
observed with entacapone. Both are recommended by the 
American Academy of Neurology to reduce off time in 
patients with motor fluctuations and dyskinesias.47 Preclinical 
data demonstrates neuroprotection in multiple neuronal 
populations subjected to various mechanisms of toxicity 
or injury, and the mechanism is not fully accounted for by 
MAO inhibition. The propargyl moiety of rasagiline may 
have neuroprotective properties, and the lack of amphetamine 
metabolites may preserve neuroprotection, in contrast to the 
first generation MAO-B inhibitor selegiline. The ADAGIO 
study seems to have suggested a disease-modifying effect 
with 1 mg/day of rasagiline, but the relevance of the 1.7 unit 
difference in total UPDRS score, and the reason that the 
higher 2 mg dose did not meet all the primary endpoints are 
debatable. Further studies may be necessary to help elucidate 
the degree of clinically meaningful disease modification that 
rasagiline has to offer.
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